The type of mismatch repair deficiency shapes dinucleotide repeat expansion and WRN inhibitor sensitivity in colorectal cancer
This study utilizes long-read sequencing to demonstrate that specific mismatch repair deficiencies in colorectal cancer differentially drive dinucleotide repeat expansions, particularly long TA repeats in MSH2-, MLH1-, and PMS2-deficient tumors, thereby defining a distinct genetic landscape where acquired resistance to WRN inhibitors is unlikely to occur.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
For decades, scientists have known that a specific type of colorectal cancer behaves differently from the rest. In these tumors, the machinery responsible for proofreading DNA during cell division has broken down. This failure leads to a condition called microsatellite instability, where tiny, repetitive stretches of genetic code become jumbled, gaining or losing letters in a way that healthy cells never do. While this instability has long been used to diagnose the disease and predict how well a patient might respond to immunotherapy, the full picture of how these errors reshape the genome has remained blurry. The real challenge lies in understanding the specific nature of these genetic glitches and whether they create a unique weakness that doctors can exploit with new drugs.
A team of researchers has now peeled back the layers of this mystery by looking at the genetic code of primary colorectal tumors with a much sharper lens than ever before. Instead of using standard sequencing methods that chop DNA into tiny, unreadable fragments, they employed a long-read technology capable of reading entire strands of DNA in one go. This approach allowed them to see what had been invisible: massive expansions of specific repeating patterns, particularly those made of the letters T and A. They discovered that these long, unstable repeats are a defining feature of tumors where the DNA repair genes MSH2, MLH1, or PMS2 are missing. However, tumors missing a different repair gene, MSH6, did not show these massive expansions at all. This distinction is crucial because it reveals that not all cancers with the same broad diagnosis are created equal; the specific gene that fails dictates the genetic landscape of the tumor.
The researchers found that these expanded T-A repeats are not just random noise; they are prone to folding into unusual, three-dimensional shapes that the cell struggles to manage. In healthy cells or those with intact repair systems, these shapes are handled without issue. But in tumors lacking specific repair genes, these structures become dangerous. The cell relies on a molecular machine called the WRN helicase to unwind and resolve these tangled DNA shapes. When the researchers tested cancer cells lacking the repair genes, they saw that blocking the WRN machine caused the tangled DNA to snap, leading to cell death. This confirmed that the presence of these specific expanded repeats makes the cancer cells dependent on the WRN machine for survival, creating a precise target for new therapies.
Crucially, the study also looked at how cancer cells might fight back against such a treatment. In the lab, the team grew cancer cells under pressure from WRN-blocking drugs to see if they could evolve resistance. They found that the cells did not survive by simply stopping the formation of the dangerous DNA shapes or by shrinking the repeats. Instead, the resistant cells developed tiny mutations directly in the WRN gene itself, altering the shape of the target so the drug could no longer bind effectively. This finding rules out the idea that resistance comes from the cancer simply fixing its DNA structure; rather, it suggests that resistance is a direct battle over the drug's ability to hit its target.
The implications of these findings are specific and grounded in the data. The study shows that tumors with expansions in T-A repeats, driven by the loss of MSH2, MLH1, or PMS2, are likely to be sensitive to drugs that block the WRN helicase. In contrast, tumors missing only MSH6 lack these expansions and appear inherently resistant to this approach. Furthermore, the research indicates that if a patient's cancer does develop resistance to such a drug, it will likely be because the cancer has mutated the drug's target, not because it has learned to avoid the DNA damage in the first place. This provides a clear roadmap for future clinical trials, suggesting that doctors should first check for these specific repeat expansions and the status of the repair genes before deciding to use WRN inhibitors, ensuring the treatment is matched to the unique genetic vulnerability of each patient's tumor.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.